✦ 24h Briefing Top Stories World U.S.India Business Technology Science Health Sports Entertainment

Loading

Fetching the latest headlines…

NabkaNews aggregates headlines from thousands of publishers worldwide via Google News, and provides AI-generated summaries and briefings for convenience. Every story links to its original source. We do not host or claim ownership of third-party reporting, and AI summaries may contain errors — always verify with the original source.

24h Briefing Top Stories World U.S.India Business Technology Science Health Sports Entertainment

Disclaimer Privacy Policy Terms of Use

© 2026 NabkaNews · World · U.S. · India — updated continuously. NabkaNews is an independent news aggregator and is not affiliated with any publisher shown.

Context Therapeutics (CNTX) Stock News · NabkaNews

← Back to headlines

Context Therapeutics (CNTX) Stock News

Stock Titan·Nov 12

This story is reported by Stock Titan. Read what other outlets are saying below, then open the original report for full details.

Full coverage

Maxim Says Context Therapeutics (CNTX)’s Share Pullback Is an Overreaction; Remains Bullish

Yahoo Finance·4d ago

Context Therapeutics joins Russell 2000 and 3000 indexes

Stock Titan·3d ago

CNTX Hits Worst Day In History After Ovarian Cancer Trial Data — But Analysts See Buying Opportunity In Dip

Stocktwits·Jun 15

Context Therapeutics Announces Positive Interim Efficacy and Safety Results from Ongoing Phase 1 Clinical Trial for CTIM-76

GlobeNewswire·Jun 15

Gapping stocks in Monday's session

ChartMill·Jun 15

New CTIM-76 data show tumor responses in platinum-resistant ovarian cancer

Stock Titan·Jun 15

Here's Why We're Not Too Worried About Context Therapeutics' (NASDAQ:CNTX) Cash Burn Situation

Yahoo Finance·Feb 5

Context Therapeutics Enters into License Agreement Amendment with BioAtla for CT-202

GlobeNewswire·May 18

View original report at Stock Titan ↗